Literature DB >> 17266524

Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6.

Chris de Graaf1, Chris Oostenbrink, Peter H J Keizers, Barbara M A van Vugt-Lussenburg, Robert A B van Waterschoot, Richard A Tschirret-Guth, Jan N M Commandeur, Nico P E Vermeulen.   

Abstract

Cytochrome P450 (CYP) 2D6 is one of the most important drug metabolizing enzymes and the rationalization and prediction of potential CYP2D6 substrates is therefore advantageous in the discovery and development of new drugs. Experimentally, the active site of CYP2D6 can be probed by site directed mutagenesis studies. Such studies can be designed from structural models of enzyme-substrate complexes. Modeling approaches can subsequently be used to rationalize the observed effect of mutations on metabolism and inhibition. The current paper will present the construction, refinement and validation of the CYP2D6 homology model used in our laboratory for the prediction and rationalisation of CYP2D6 substrate metabolism and CYP2D6-ligand interactions. The model could explain reported site-directed mutagenesis data (for example, mutation of E216 and D301). Furthermore, based on the model, new CYP2D6 mutants were constructed and studied in our lab, and also for these mutants a rationalization of experimentally observed characteristics could be achieved (I106E, F120A, T309V, F483A). CYP2D6-substrate interaction fingerprint analysis of docked substrates in our homology model suggests that several other active site residues are probably interacting with ligands as well, opening the way for further mutagenesis studies. Our homology model was found to agree with most of the details of the recently solved substrate-free CYP2D6 crystal structure [Rowland et al. J. Biol. Chem. 2006, 281, 7614-7622]. Structural differences between the homology model and crystal structure were the same differences observed between substrate-free and substrate-bound structures of other CYPs, suggesting that these conformational changes are required upon substrate binding. The CYP2D6 crystal structure further validates our homology modeling approach and shows that computational chemistry is a useful and valuable tool to provide models for substrate-bound complexes of CYPs which give insight into CYP-ligand interactions. This information is essential for successful pre-experimental virtual screening, as well as accurate hypothesis generation for in vitro studies in drug discovery and development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266524     DOI: 10.2174/138920007779315062

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  15 in total

Review 1.  Conformational plasticity and structure/function relationships in cytochromes P450.

Authors:  Thomas C Pochapsky; Sophia Kazanis; Marina Dang
Journal:  Antioxid Redox Signal       Date:  2010-10       Impact factor: 8.401

2.  Molecular dynamics simulations give insight into the conformational change, complex formation, and electron transfer pathway for cytochrome P450 reductase.

Authors:  Axel Sündermann; Chris Oostenbrink
Journal:  Protein Sci       Date:  2013-08-01       Impact factor: 6.725

3.  Lead optimization mapper: automating free energy calculations for lead optimization.

Authors:  Shuai Liu; Yujie Wu; Teng Lin; Robert Abel; Jonathan P Redmann; Christopher M Summa; Vivian R Jaber; Nathan M Lim; David L Mobley
Journal:  J Comput Aided Mol Des       Date:  2013-09-26       Impact factor: 3.686

4.  Perspective: Alchemical free energy calculations for drug discovery.

Authors:  David L Mobley; Pavel V Klimovich
Journal:  J Chem Phys       Date:  2012-12-21       Impact factor: 3.488

5.  Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.

Authors:  Rayomand J Unwalla; Jason B Cross; Sumeet Salaniwal; Adam D Shilling; Louis Leung; John Kao; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2010-04-02       Impact factor: 3.686

6.  Free energies of binding of R- and S-propranolol to wild-type and F483A mutant cytochrome P450 2D6 from molecular dynamics simulations.

Authors:  Chris de Graaf; Chris Oostenbrink; Peter H J Keizers; Barbara M A van Vugt-Lussenburg; Jan N M Commandeur; Nico P E Vermeulen
Journal:  Eur Biophys J       Date:  2007-02-27       Impact factor: 1.733

7.  Molecular dynamics analysis reveals structural insights into mechanism of nicotine N-demethylation catalyzed by tobacco cytochrome P450 mono-oxygenase.

Authors:  Shan Wang; Shuo Yang; Baiyi An; Shichen Wang; Yuejia Yin; Yang Lu; Ying Xu; Dongyun Hao
Journal:  PLoS One       Date:  2011-08-16       Impact factor: 3.240

8.  Functional characterization of a first avian cytochrome P450 of the CYP2D subfamily (CYP2D49).

Authors:  Hua Cai; Jun Jiang; Qi Yang; Qingmei Chen; Yiqun Deng
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

9.  Rationalization of stereospecific binding of propranolol to cytochrome P450 2D6 by free energy calculations.

Authors:  Gabor Nagy; Chris Oostenbrink
Journal:  Eur Biophys J       Date:  2012-10-20       Impact factor: 1.733

10.  Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.

Authors:  Alice Matimba; Jurgen Del-Favero; Christine Van Broeckhoven; Collen Masimirembwa
Journal:  Hum Genomics       Date:  2009-01       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.